OBX-115 cell therapy for advanced melanoma or lung cancer
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial tests an experimental cell therapy called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments. The therapy uses your own immune cells to fight the cancer. The study aims to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced melanoma or non-small cell lung cancer that has spread or come back after treatment.
- You must have a tumor that can be surgically removed to make the cell therapy, and at least one other measurable tumor left after that surgery.
- You must be well enough to perform daily activities (ECOG score 0 or 1) and have a life expectancy of more than 6 months.
- You must have recovered from all side effects of previous cancer treatments.
- You must have adequate bone marrow, heart, liver, lung, and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
This trial studies how well and how safely an infusion called IOV-4001 works in adults with advanced melanoma or non-small-cell lung cancer that cannot be removed with surgery. It also aims to see what side effects occur and whether the treatment can help control the cancer.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
This trial studies OH2 injection given directly into a melanoma tumor, combined with HX008, to see if it can shrink tumors after standard treatments—including PD-1—did not work. It may help people with advanced melanoma, especially when there is a reachable tumor for injection.
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.